✦ LIBER ✦

844 IN VITRO CHARACTERIZATION OF THE PAN-GENOTYPE ACTIVITY OF THE HCV NS3/4A PROTEASE INHIBITORS BOCEPREVIR AND TELAPREVIR

✍ Scribed by J.A. Howe; D. Graham; P. McMonagle; S. Curry; R. Chase; F. Lahser; R.A. Ogert; J. Strizki; R.J.B.O. Barnard; R. Zhang; G. Zhuyan; M. Treitel; D.J. Hazuda; A.Y. Howe

Book ID: 117381052
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 61 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(12)60856-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A novel HCV NS3 protease mutation select

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors

✍ Robert Chase; Angela Skelton; Ellen Xia; Stephanie Curry; Shaotang Liu; Patricia 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 609 KB

758 CHARACTERIZATION OF RESISTANT MUTANT

758 CHARACTERIZATION OF RESISTANT MUTANTS SELECTED IN VITRO BY THE HCV NS3/4A PROTEASE INHIBITOR BI 201335

✍ G. Kukolj; C. Bousquet; N. Dansereau; F. Dô; L. Lagacé; M. Llinàs-Brunet; M. Mar 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

954 BI 201335, A POTENT HCV NS3 PROTEASE

954 BI 201335, A POTENT HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE AND -EXPERIENCED CHRONIC HCV GENOTYPE-1 INFECTION: GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE NS3 PROTEASE DOMAIN

✍ G. Kukolj; Y. Benhamou; M.P. Manns; M. Bourlière; S. Pol; M. Schuchmann; M. Cart 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Characterization of vaniprevir, a hepati

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

✍ Lawitz, Eric; Sulkowski, Mark; Jacobson, Ira; Kraft, Walter K.; Maliakkal, Bened 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 367 KB

63 CHARACTERIZATION OF VIROLOGIC ESCAPE

63 CHARACTERIZATION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1 NULL RESPONDERS RECEIVING A COMBINATION OF THE NS3 PROTEASE INHIBITOR BMS-650032 AND NS5A INHIBITOR BMS-790052

✍ F. McPhee; D. Hernandez; F. Yu; J. Ueland; C. Wang; H. Huang; D. Gardiner; R. Fr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Potency, safety, and pharmacokinetics of

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

✍ Michael P. Manns; Marc Bourlière; Yves Benhamou; Stanislas Pol; Maurizio Bonacin 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 767 KB